



## Arbutus to Participate in Upcoming Investor Conferences

September 26, 2019

WARMINSTER, Pa., Sept. 26, 2019 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that the Company will be participating in the following investor conferences in October 2019:

### **Cantor Fitzgerald Global Healthcare Conference – New York**

Friday, October 4, 2019, 1:10 PM ET

Presentation: William H. Collier

### **Chardan Genetic Medicines Conference – New York**

Monday, October 7, 2019, 8:00 AM ET

Fireside Chat: William H. Collier and Dr. Gaston Picchio

Live webcasts of the presentations can be accessed through the Investors section of Arbutus' website at [www.arbutusbio.com](http://www.arbutusbio.com). A replay of the webcasts will be available for 90 days following the live presentations.

### **About Arbutus**

Arbutus Biopharma Corporation is a publicly-traded (Nasdaq: ABUS) biopharmaceutical company dedicated to discovering, developing, and commercializing a cure for patients suffering from chronic Hepatitis B infection. Arbutus is developing multiple drug candidates, each of which have the potential to improve upon the standard of care and contribute to a curative combination regimen. For more information, visit [www.arbutusbio.com](http://www.arbutusbio.com).

### **Contact Information**

#### **Investors**

William H. Collier

President and CEO

Phone: 604-419-3200

Email: [ir@arbutusbio.com](mailto:ir@arbutusbio.com)

#### **Media**

Pam Murphy

Investor Relations Consultant

Phone: 604-419-3200

Email: [ir@arbutusbio.com](mailto:ir@arbutusbio.com)



Source: Arbutus Biopharma Corporation